Purpose: To ensure appropriate selection of patients and quality assurance, the LIBERATE clinical registry has been developed which monitors men who have undergone focal brachytherapy for prostate cancer. The registry is Icon Cancer Centre initiated.
LIBERATE aims to provide proof of concept that focal brachytherapy minimises side effects that are commonly seen in treating the whole prostate for men with low to intermediate risk prostate cancer.
LIBERATE is the only registry monitoring patients who have undergone focal brachytherapy.
To be considered for the registry or for further information, please contact: